Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
Phase 3 trial using the SYK inhibitor, entospletinib, in combination with standard induction and consolidation chemotherapy in newly diagnosed, NPM1 mutated Acute Myelogenous Leukemia
NCT Number:
NCT05020665
Phase:
III
Protocol Type:
Treatment
Age Group:
Adult
Disease Sites:
Myeloid and Monocytic Leukemia
Study Objectives:
The primary objective of this study is to evaluate the efficacy of entospletinib (ENTO) compared to placebo when added to chemotherapy in previously untreated nucleophosmin-1 mutated (NPM1-m) acute myeloid leukemia (AML), as defined by the rate of molecularly defined measurable residual disease (MRD).
For more information about the trial above please contact the study team:
Trial opened at the following institutions: Medical University of South Carolina
Study Documents
(MUSC NetID required for document access)